ACADIA Pharmaceuticals Inc.

Earnings are forecast to grow 132.43% next year, from $0.37 to $0.86 per share, and major institutions like Citigroup and B of A Securities have raised their price targets to $35 and $30 respectively, maintaining Buy ratings and signaling strong confidence in profitability recovery.

EPS estimates have been sharply revised downward from $0.709 to $0.442, and net income is forecast to shrink 80% next year — a far steeper decline than the 9.4% projected for the broader U.S. biotechs industry, raising serious concerns about near-term profitability.

ACADIA posted 2025 revenue of $1.07B with a 34.3% net income margin, and Q1 2026 revenue grew 9.7% year-over-year to $268.1M. The company issued FY 2026 revenue guidance of $1.2B–$1.3B, with steady commercial momentum from both Nuplazid and Daybue underpinning confidence in sustained growth.

Q1 2026 earnings missed consensus estimates, with reported EPS of $0.02 versus the expected $0.04, and quarterly revenue of $268.1M fell short of the $280.25M analyst consensus. These misses, combined with a steep 50% cut to Daybue's wholesale acquisition cost, point to material execution and pricing risks.

The CHMP issued a positive recommendation for Daybue in Europe as of June 26, 2026, opening a significant new market. Additionally, pipeline catalyst remlifanserin represents a potential upside driver, and the consensus price target of $34.25 with 70% buy ratings reflects broad analyst optimism around these growth opportunities.

Despite pipeline activity, ACADIA's stock carries a high EV/EBITDA of 38.72 and a forward P/E of 69.19, suggesting the market has already priced in optimistic scenarios. Insider selling and competitive pressures in neurology markets introduce meaningful downside risk if pipeline or European commercial execution disappoints.